

Comprehensive Understanding of Readiness for Elimination of Hepatitis C in Corrections (Cure-HepC)

Form Approved OMB No. 0920-XXXX Exp. Date xx/xx/20xx

Public reporting burden of this collection of information varies from 30 to 80 minutes with an estimated time to complete of 55 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-XXXX). The goal of this survey is to understand practices surrounding hepatitis C virus screening, testing, and treatment and the national burden of hepatitis C in carceral settings. Each responding system will receive a request to complete this web-based survey with advance notification to allow time for record searches. Your survey team will provide you with a unique system identifier that cannot be tied directly to the system answering this survey. The survey has branching logic to improve efficiency and reduce the time burden for completing this survey. Participating systems will have a set-time period, as determined by the survey team, to complete the survey. The survey will be self-administered. If preferred, there will be an option to complete an interviewer-administered survey via telephone or videoconferencing and this request should be made directly to the survey team. Please answer the survey questions to the best of your ability. The information you provide will be reported in aggregate and only released externally with your explicit permission. The analysis period for this survey is defined as the most recent complete calendar year. Thank you!

Today's date

Unique system identifier

 ((Please only use unique identifier provided by survey team))

The first set of questions are about your system during the analysis period.

1. During the analysis period, what was the classification of your system?

- State Prison System
 Jail
 Unified System (both state prison and jail within a single administration)

2. During the analysis period, was your system under court order or consent decree related to management of patients with hepatitis C infection?

- Yes, presently
 No, presently
 In the past, but not presently
 Other

Other, please explain:

3. During the analysis period, what was the total bed capacity in your system?

 ((Please answer in whole numbers))

4. During the analysis period, what was the average length of stay (in days) of the confined and/or detained population in your system?

 (Please answer in whole numbers))

5. During the analysis period, what was the average daily census of the confined and/or detained population in your system?

 (Please answer in whole numbers))

5a. During the analysis period, what was the average daily census of the confined and/or detained population in your system by sex assigned at birth? (Please answer in whole numbers).

Males

Females _____

Other/Missing/Unknown

5b. During the analysis period, what was the average daily census of the confined and/or detained population in your system by race/ethnicity? (Please answer in whole numbers).

American Indian or Alaska Native _____

Asian _____

Black or African American _____

Hispanic or Latino _____

Middle Eastern or North African _____

Native Hawaiian or Pacific Islander _____

White _____

Other/Missing/Unknown _____

5c. During the analysis period, what was the average daily census of the confined and/or detained population in your system by age? (Please answer in whole numbers).

Less than 21 years old

21-29 years old

30-39 years old

40-49 years old

50-59 years old

60 years old and older

6. The answer to the above questions were:

- Estimated
 Measured based on available data

The next set of questions are about hepatitis C virus (HCV) testing practices within your system during the analysis period.

HCV screening consists of testing for the presence of antibodies to HCV, and if reactive, testing for HCV RNA to diagnose current infection.

Reflex testing means automatically performing HCV RNA testing on patients with a reactive HCV antibody using the same blood sample. HCV screening may consist of single-step HCV RNA testing for populations with high rates of recent HCV exposure.

7. During the analysis period, what type of HCV screening/testing was used by your system?

- HCV antibody only
 HCV antibody and HCV RNA testing
 I do not know
 Other

Other, please explain:

7a. During the analysis period, was HCV antibody to HCV RNA reflex testing performed by your system?

- Yes
 No
 I do not know
 Other
 ((Reflex testing means HCV RNA testing is performed automatically on patients with a positive HCV antibody using the same blood sample))

Other, please explain:

8. During the analysis period, which HCV screening methodologies did your system employ? (Please select all that apply).

- At intake or History and Physical exam: universal screening, opt-out (performed unless patient refuses)
 At intake or History and Physical exam: universal screening, opt-in (offered, performed if patient agrees)
 At intake or History and Physical exam: risk-based testing per provider order
 Annual or periodic testing for those at risk
 Anytime testing per provider order
 At discharge: universal screening, opt-out (performed unless patient refuses)
 At discharge: universal screening, opt-in (offered, performed if patient agrees)
 At discharge: risk-based testing per provider order
 Other

Other, please explain:

The next set of questions are about hepatitis C virus (HCV) antibody and HCV RNA positivity among intakes within your system during the analysis period.

9. During the analysis period, what was the total number of intakes into your system?

_____ ((Please answer in whole numbers))

10. During the analysis period, how many intakes were tested for HCV antibody?

_____ ((Please answer in whole numbers))

11. During the analysis period, among intakes tested for HCV antibody, how many tested positive for HCV antibody?

_____ ((Please answer in whole numbers))

12. During the analysis period, among intakes who tested positive for HCV antibody, how many were tested for HCV RNA?

_____ ((Please answer in whole numbers))

13. During the analysis period, among intakes tested for HCV RNA, how many tested positive for HCV RNA?

_____ (Please answer in whole numbers)

13a. During the analysis period, how many intakes tested positive for HCV RNA by sex assigned at birth? (Please answer in whole numbers).

Males

Females _____

Other/Missing/Unknown

13b. During the analysis period, how many intakes tested positive for HCV RNA by race/ethnicity? (Please answer in whole numbers).

American Indian or Alaska Native _____

Asian _____

Black or African American _____

Hispanic or Latino _____

Middle Eastern or North African _____

Native Hawaiian or Pacific Islander _____

White _____

Other/Missing/Unknown _____

13c. During the analysis period, how many of intakes tested positive for HCV RNA by age?
(Please answer in whole numbers).

Less than 21 years old

21 - 29 years old

30 - 39 years old

40- 49 years old

50 - 59 years old

60 years old and older

14. The answer to the above questions were:

Estimated

Measured based on available data

The next set of question are about determining a hepatitis C virus (HCV) mid-year point prevalence estimate among the total confined and/or detained population within your system.

For the following questions, you may enter values based on your best estimates. If you are able to measure these values precisely, assess the HCV test results using data from people residing in your system at the mid-year point (July 1) then use the most recent test results up to the end of the analysis period (December 31).

15. At the mid-year point, how many people were confined and/or detained within your system?

((Please answer in whole numbers))

16. Among those confined and/or detained at the mid-year point, how many had been tested for HCV antibody by the end of the analysis period?

((Please answer in whole numbers))

17. Among those confined and/or detained at the mid-year point who were tested for HCV antibody by the end of the analysis period, how many tested positive for HCV antibody?

((Please answer in whole numbers))

18. Among those confined and/or detained at the mid-year point who had tested positive for HCV antibody, how many were tested for HCV RNA by the end of the analysis period?

((Please answer in whole numbers))

19. Among those confined and/or detained at the mid-year point who were tested for HCV RNA by the end of the analysis period, how many tested positive for HCV RNA?

((Please answer in whole numbers))

19a. At the mid-year point, how many of your confined and/or detained population tested positive for HCV RNA by sex assigned at birth? (Please answer in whole numbers).

Males

Females _____

Other/Missing/Unknown

19b. At the mid-year point, how many of your confined and/or detained population tested positive for HCV RNA by race/ethnicity? (Please answer in whole numbers).

American Indian or Alaska Native _____

Asian _____

Black or African American _____

Hispanic or Latino _____

Middle Eastern or North African _____

Native Hawaiian or Pacific Islander _____

White _____

Other/Missing/Unknown _____

19c. At the mid-year point, how many of your confined and/or detained population tested positive for HCV RNA by age? (Please answer in whole numbers).

Less than 21 years old

21 - 29 years old

40- 49 years old

50 - 59 years old

60 years old and older

20. The answer to the above questions were:

- Estimated
 Measured based on available data

The next set of questions are about hepatitis C treatment practices within your system during the analysis period.

21. During the analysis period, what criteria was utilized to select and prioritize your confined and/or detained population who had hepatitis C infection for treatment?

(Please select all that apply).

- Length of stay
 Blood tests (i.e., liver function test, APRI, FIB-4)
 Presence of co-existing illness
 Liver imaging
 Age
 Participation in substance use treatment or programming
 Previous history of hepatitis C treatment
 History of discipline and/or incidents during current confinement
 None, universal hepatitis C treatment policy
 Other

Other, please explain:

22. During the analysis period, how many unique individuals did your system initiate treatment for hepatitis C infection?

((Please answer in whole numbers))

23. During the analysis period, which clinical practice guideline(s) did you use to initiate treatment for your confined and/or detained population for hepatitis C infection?

(Please select all that apply).

- American Association for the Study of Liver Diseases (AASLD) HCV guidance
 Federal Bureau of Prisons HCV clinical guidance
 In-house developed HCV clinical guidance
 Patient seen by outside specialist
 Not applicable
 Other

Other, please explain:

24. During the analysis period, did you offer substance use disorder treatment to your confined and/or detained population undergoing treatment for hepatitis C infection?

- Yes
 No
 Other

Other, please explain:

25. During the analysis period, did you offer medication for opioid use disorder (MOUD) to your confined and/or detained population undergoing treatment for hepatitis C infection who have an opioid use disorder?

- Yes
 No
 Other

Other, please explain:

The next set of questions are about hepatitis C treatment opportunities and barriers within your system.

26. Please identify challenges you have encountered in your efforts to treat your confined and/or detained population who have hepatitis C infection.

(Please select all that apply).

- Medication cost
 Medication access
 Inadequate nursing staffing
 Laboratory cost
 Laboratory access
 In-house provider access/adequacy
 Specialist Provider access/adequacy
 Patient non-compliance
 Linkage to community providers on discharge
 Access to medical services on discharge
 No or Inadequate data systems
 Length of stay
 None of the above
 Other

Other, please explain:

27. What is your single greatest challenge in testing and treating your confined and/or detained population who have hepatitis C infection?

 ((Please thoroughly explain))

28. Is there anything else you would like to convey regarding your ability to test and treat hepatitis C infection among your confined and/or detained population?

 ((Please thoroughly explain))